Member Directory
Our Biosciences Team has advised on a wide variety of matters including research and development agreements, patent and know how licences and assignments, manufacturing agreements, bioinformatics, regulatory matters, clinical trials, patent litigation and competition law. The members of the Biosciences Team pride themselves on their responsive, hands-on and pro-active approach. This includes helping to find venture capital finance for clients through the firm's extensive corporate finance network and advising on intellectual property protection and exploitation. Osborne Clarke recognises that biotechnology companies want to deal with a team of specialists whose experience ensures technically accurate and commercial, pragmatic advice.. . Biotechnology agreements, collaborations, research and devleopment agreements, venture capital and other funding arrangements for biotechnology companies. Represented in most major European jurisdictions and in Silicon Valley.. . Bioinformatics, law, European law, research, colllaboration, contract research, intellectual property, patents, financing, competition law, technology transfer, mergers and acquisitions, due diligence, regulatory matters.
Spun out from the Karolinska Institute in 2013, Pelago Bioscience AB was founded by the inventors of the Cellular Thermal Shift Assay (CETSA®) to both develop the method and to provide a commercial service for organisations wanting to use the method.. . CETSA measures compound binding under actual physiological conditions within either a cellular of lysate environment. The assay relies on a well-established observation that compound binding with a protein will change its thermal denaturation point, meaning that at a given denaturation temperature there will be a difference in the abundance of the intact protein as compared with a negative control. It is the only technique that will confirm such target engagement is occurring and provides ‘real world’ EC50 values for your compound in cells.. . The company controls the patents on CETSA and delivers in situ target engagement studies to accelerate preclinical and clinical drug discovery and diagnostics development. Using CETSA data and applications, drug discovery R&D companies are able to make better and more informed decisions at earlier stages in their projects.
Pharma International provides global pharmaceutical regulatory consultancy services, with an emphasis on the emerging markets. Fully licensed by Swissmedic, Pharma International is authorised to trade in biotechnology, pharmaceuticals and medical devices internationally – as well as providing Swiss Qualified Person services. Seminars on regulatory affairs, especially Asia including ASEAN, China, Korea and India, are conducted regularly and can be adapted to in-house requirements.
Regulatory Consultancy
PharmaMedic provides a comprehensive outsourced virtual medical and regulatory affairs service for start-ups, mid to late-stage biopharma, as well as consumer health organisations, medical device companies, and academic centres. We deliver our virtual medical and regulatory affairs solutions through a team of experienced pharmaceutical consultants. We provide a range of flexible services supporting start-ups, product launches, and large pharma teams.
For more information visit our website https://pharmamedic.co/
Download our capabilities brochure here https://pharmamedic.co/wp-content/uploads/2020/09/PMC-Capabilities.pdf
Watch our Member Showcase Video https://bit.ly/3rzlfvd
Pharmaron (Stock Code: 300759.SZ/3759.HK) is a premier R&D service provider for the life sciences industry. Founded in 2004, Pharmaron has invested in its people and facilities, and established a broad spectrum of research, development and manufacturing service capabilities throughout the entire drug discovery, preclinical and clinical development process across multiple therapeutic modalities, including small molecules, biologics and CGT products. With over 15,000 employees, and operations in China, the U.S., and the U.K., Pharmaron has an excellent track record in the delivery of R&D solutions to its partners in North America, Europe, Japan and China. For more information, visit: https://www.pharmaron.com
PhoreMost™ is focused on bringing more effective and affordable targeted medicines to patients. To achieve this aim, PhoreMost is developing a next-generation phenotypic screening technology that can discern the best new targets for future therapy and crucially, how to drug them. This has the potential to significantly increase the diversity of novel therapeutics for cancer and other unmet diseases. Based on the company's proprietary Protein Interference (PROTEINi®) technology, PhoreMost has developed SITESEEKER®; a platform that can systematically unmask cryptic druggable sites in the human genome and then link them to useful therapeutic functions in a live-cell context.